Security
Agios Pharmaceuticals, Inc. Common Stock · AGIO
AGIONASDAQCommon stockCurrentCIK 1439222Updated Oct 29, 2026
Name history
AGIOS PHARMACEUTICALS INC · through Jul 16, 2019
AGIO price & chart
Loading TradingView…
NASDAQ:AGIO on TradingView ↗About the company
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities - collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO ↗
Recent filings
Show 5 more recent filings
4 filing
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
SCHEDULE 13G/A - filed by ARMISTICE CAPITAL, LLC regarding AGIOS PHARMACEUTICALS, INC.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,385,705,000Source | 1,791,794,000Source | 1,108,424,000Source | 1,471,237,000Source | 773,063,000Source | 1,184,990,000Source | 1,555,518,000Source | 849,709,000Source | 1,297,225,000Source | 1,663,199,000Source | 937,118,000Source | 1,238,718,000Source |
| Property, Plant and Equipment, NetUSD | 10,675,000Source | 11,819,000Source | 9,946,000Source | 10,579,000Source | 12,726,000Source | 10,566,000Source | 11,067,000Source | 14,119,000Source | 10,775,000Source | 11,675,000Source | 15,382,000Source | 22,987,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 92,710,000Source | 253,730,000Source | 99,647,000Source | 80,871,000Source | 84,518,000Source | 113,600,000Source | 78,964,000Source | 118,764,000Source | 89,130,000Source | 76,247,000Source | 88,205,000Source | 139,259,000Source |
| Inventory, NetUSD | 32,034,000Source | 26,429,000Source | 35,752,000Source | 30,848,000Source | 23,937,000Source | 35,087,000Source | 29,605,000Source | 23,070,000Source | 32,920,000Source | 27,616,000Source | 19,076,000Source | 8,492,000Source |
| Assets, CurrentUSD | 1,033,109,000Source | 1,074,189,000Source | 717,668,000Source | 1,019,464,000Source | 632,127,000Source | 834,843,000Source | 968,616,000Source | 663,627,000Source | 942,052,000Source | 965,600,000Source | 833,835,000Source | 832,772,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 43,186,000Source | 39,885,000Source | 45,724,000Source | 44,693,000Source | 34,536,000Source | 46,586,000Source | 42,292,000Source | 39,113,000Source | 44,130,000Source | 40,165,000Source | 35,021,000Source | 38,955,000Source |
| Operating Lease, Right-of-Use AssetUSD | 33,650,000Source | 45,841,000Source | 23,875,000Source | 36,785,000Source | 48,750,000Source | 27,196,000Source | 39,861,000Source | 51,606,000Source | 30,454,000Source | 42,879,000Source | 54,409,000Source | 65,129,000Source |
| Other Assets, NoncurrentUSD | 3,930,000Source | 4,056,000Source | 9,681,000Source | 3,942,000Source | 4,056,000Source | 3,931,000Source | 4,721,000Source | 4,056,000Source | 3,931,000Source | 4,724,000Source | 4,057,000Source | 3,956,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 101,375,000Source | 165,122,000Source | 82,403,000Source | 101,682,000Source | 112,553,000Source | 75,875,000Source | 88,990,000Source | 105,787,000Source | 104,111,000Source | 122,243,000Source | 126,099,000Source | 137,904,000Source |
| Stockholders’ equity: | ||||||||||||
| Retained Earnings (Accumulated Deficit)USD | -453,666,000Source | -52,401,000Source | -761,519,000Source | -350,233,000Source | -1,000,316,000Source | -660,816,000Source | -238,213,000Source | -904,198,000Source | -561,705,000Source | -148,924,000Source | -822,649,000Source | -470,561,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,284,330,000Source | 1,626,672,000Source | 1,026,021,000Source | 1,369,555,000Source | 660,510,000Source | 1,109,115,000Source | 1,466,528,000Source | 743,922,000Source | 1,193,114,000Source | 1,540,956,000Source | 811,019,000Source | 1,100,814,000Source |
| Additional Paid in Capital, Common StockUSD | 2,538,357,000Source | 2,478,066,000Source | 2,591,745,000Source | 2,521,545,000Source | 2,464,284,000Source | 2,572,655,000Source | 2,506,788,000Source | 2,451,620,000Source | 2,555,037,000Source | 2,493,811,000Source | 2,436,523,000Source | 2,386,325,000Source |
| Liabilities and EquityUSD | 1,385,705,000Source | 1,791,794,000Source | 1,108,424,000Source | 1,471,237,000Source | 773,063,000Source | 1,184,990,000Source | 1,555,518,000Source | 849,709,000Source | 1,297,225,000Source | 1,663,199,000Source | 937,118,000Source | 1,238,718,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 74,757,000Source | 119,451,000Source | 70,217,000Source | 70,410,000Source | 62,637,000Source | 58,845,000Source | 52,366,000Source | 51,691,000Source | 82,206,000Source | 81,156,000Source | 67,955,000Source | 62,629,000Source |
| Operating Lease, Liability, CurrentUSD | 17,987,000Source | 16,319,000Source | 19,225,000Source | 17,589,000Source | 15,860,000Source | 18,805,000Source | 17,196,000Source | 15,407,000Source | 18,392,000Source | 16,781,000Source | 15,008,000Source | 13,663,000Source |
| Accounts Payable, CurrentUSD | 19,553,000Source | 17,143,000Source | 16,345,000Source | 17,532,000Source | 10,035,000Source | 13,747,000Source | 13,726,000Source | 11,155,000Source | 18,355,000Source | 16,643,000Source | 9,780,000Source | 18,616,000Source |
| Operating Lease, Liability, NoncurrentUSD | 26,528,000Source | 44,515,000Source | 11,946,000Source | 31,171,000Source | 48,760,000Source | 16,940,000Source | 35,744,000Source | 52,940,000Source | 21,815,000Source | 40,207,000Source | 56,988,000Source | 71,996,000Source |
| Other Liabilities, NoncurrentUSD | 90,000Source | 1,156,000Source | 240,000Source | 101,000Source | 1,156,000Source | 90,000Source | 880,000Source | 1,156,000Source | 90,000Source | 880,000Source | 1,156,000Source | 3,279,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 37,217,000Source | 33,307,000Source | 34,647,000Source | 35,289,000Source | 36,742,000Source | 26,293,000Source | 20,761,000Source | 25,129,000Source | 45,459,000Source | 46,861,000Source | 43,167,000Source | 30,350,000Source |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | 2,051,000Source | 3,420,000Source | -1,795,000Source | 655,000Source | -1,045,000Source | -314,000Source | 365,000Source | -1,087,000Source | 2,193,000Source | -1,518,000Source | -441,000Source | -12,535,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,300,000,000Source | 1,700,000,000Source | 1,000,000,000Source | 1,300,000,000Source | 645,300,000Source | 1,000,000,000Source | 1,400,000,000Source | 714,300,000Source | 1,200,000,000Source | 1,500,000,000Source | 806,400,000Source | 1,100,000,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 15,541,000Source | 11,359,000Source | 52,552,000Source | 42,847,000Source | 44,766,000Source | 49,296,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 5,555,000Source | -765,000Source | 6,468,000Source | 1,299,000Source | 604,000Source | 2,206,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,167,000Source | 1,989,000Source | 5,304,000Source | 8,540,000Source | 10,584,000Source | 8,492,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -4,993,000Source | -2,821,000Source | 1,746,000Source | 6,601,000Source | -8,733,000Source | 3,436,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -118,920,000Source | -111,489,000Source | -372,977,000Source | -389,841,000Source | -296,062,000Source | -309,478,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 141,312,000Source | 112,587,000Source | 377,184,000Source | 363,441,000Source | 239,575,000Source | 243,261,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 769,000Source | 766,000Source | 4,316,000Source | 1,685,000Source | 999,000Source | 4,881,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,078,000Source | 1,619,000Source | 8,676,000Source | 14,442,000Source | 5,433,000Source | 2,350,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 24,470,000Source | 2,717,000Source | 12,883,000Source | -11,958,000Source | -51,054,000Source | -63,867,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 92,710,000Source | 253,730,000Source | 99,647,000Source | 80,871,000Source | 113,600,000Source | 78,964,000Source | 89,130,000Source | 76,247,000Source | 88,205,000Source | 139,259,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 4,000Source | 188,000Source | 628,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 12,377,000Source | 11,145,000Source | 15,941,000Source | 14,692,000Source | 15,541,000Source | 11,359,000Source | 52,552,000Source | 42,847,000Source | 44,766,000Source | 49,296,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,300,000,000Source | 1,700,000,000Source | 1,000,000,000Source | 1,300,000,000Source | 1,000,000,000Source | 1,400,000,000Source | 1,200,000,000Source | 1,500,000,000Source | 806,400,000Source | 1,100,000,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 5,200,000Source | 5,700,000Source | 6,600,000Source | 8,400,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | 0Source | 200,000,000Source | — | — | — | — | 0Source | 200,000,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | -5,000Source | 39,000Source | -553,000Source | 48,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | -352,088,000Source | -231,801,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 53,120,000Source | — | — | — | — | -1,016,000Source | 44,244,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 12,793,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -103,433,000Source | 947,915,000Source | -100,703,000Source | -112,020,000Source | -99,111,000Source | -89,289,000Source | -412,781,000Source | 673,725,000Source | -352,088,000Source | -231,801,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 67,000Source | 1,651,000Source | 119,000Source | 523,000Source | 119,000Source | 1,253,000Source | 1,956,000Source | 6,487,000Source | 6,055,000Source | 6,749,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 28,000Source | 2,000Source | 118,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 12,880,000Source | 8,964,000Source | 44,745,000Source | 12,455,000Source | 20,746,000Source | 8,726,000Source | 54,028,000Source | 36,498,000Source | 26,823,000Source | 14,240,000Source |
| Cost of RevenueUSD | — | — | 1,679,000Source | 783,000Source | 2,996,000Source | 1,702,000Source | 1,319,000Source | 1,085,000Source | 6,345,000Source | 4,165,000Source | 2,881,000Source | 1,704,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 41,274,000Source | 38,537,000Source | 51,547,000Source | 45,869,000Source | 48,304,000Source | 41,527,000Source | 180,280,000Source | 156,784,000Source | 119,903,000Source | 121,673,000Source |
| Operating Income (Loss)USD | — | — | -116,869,000Source | -102,811,000Source | -110,552,000Source | -127,056,000Source | -110,025,000Source | -106,629,000Source | -472,132,000Source | -425,737,000Source | -391,487,000Source | -389,047,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 67,000Source | 1,651,000Source | 119,000Source | 523,000Source | 119,000Source | 1,253,000Source | 1,956,000Source | 6,487,000Source | 6,055,000Source | 6,749,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -103,433,000Source | 1,001,035,000Source | — | — | — | — | -413,797,000Source | 717,969,000Source | -352,088,000Source | -231,801,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 53,120,000Source | — | — | — | — | -1,016,000Source | 44,244,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -103,433,000Source | 947,915,000Source | -100,703,000Source | -112,020,000Source | -99,111,000Source | -89,289,000Source | -412,781,000Source | 673,725,000Source | -352,088,000Source | -231,801,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.78Source | 16.65Source | -1.69Source | -1.93Source | -1.69Source | -1.55Source | -7.12Source | 11.86Source | -6.33Source | -4.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.78Source | 16.22Source | -1.69Source | -1.93Source | -1.69Source | -1.55Source | -7.12Source | 11.64Source | -6.33Source | -4.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 58,139,277Source | 56,939,403Source | 59,488,871Source | 57,932,576Source | 58,782,241Source | 57,459,195Source | 57,972,004Source | 56,807,415Source | 55,651,487Source | 54,789,435Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 58,139,277Source | 58,432,796Source | 59,488,871Source | 57,932,576Source | 58,782,241Source | 57,459,195Source | 57,972,004Source | 57,889,255Source | 55,651,487Source | 54,789,435Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 129,749,000Source | 111,775,000Source | 155,297,000Source | 139,511,000Source | 130,771,000Source | 115,355,000Source | 526,160,000Source | 462,235,000Source | 418,310,000Source | 403,287,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | -352,088,000Source | -231,801,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -413,806,000Source | 717,967,000Source | -352,085,000Source | -231,767,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | — | — | — | — | — | — | -6.33Source | -4.23Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | — | — | — | — | — | — | -6.33Source | -4.23Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 13,369,000Source | 13,059,000Source | 9,730,000Source | 14,513,000Source | 10,795,000Source | 16,087,000Source | 56,379,000Source | 48,083,000Source | 33,344,000Source | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 12,793,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 28,000Source | 2,000Source | 118,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 86,796,000Source | 72,455,000Source | 100,754,000Source | 91,940,000Source | 81,148,000Source | 72,743,000Source | 339,535,000Source | 301,286,000Source | 295,526,000Source | 279,910,000Source |
Offerings
Registration 333-293421
Filing attachments
d57571dex991.htm · S-8 · 2026-06-18
Exhibit 99.1 AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, AS AMENDED Purpose The purpose of this 2023 Stock Incentive Plan (the “Plan”) of Agios Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performan…
Read attachment ↗d71681dex44.htm · S-3ASR · 2026-02-12
Exhibit 4.4 AGIOS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of _______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Section of Indenture Trust Indenture Act of 1939, as amended ───────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) …
Read attachment ↗d71681dex45.htm · S-3ASR · 2026-02-12
Exhibit 4.5 AGIOS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of _______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act Section of Indenture of 1939, as amended ──────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.086.10 310(c) Inapplicable 311(a) …
Read attachment ↗d71681dex46.htm · S-3ASR · 2026-02-12
Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF S…
Read attachment ↗d71681dex47.htm · S-3ASR · 2026-02-12
Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINE…
Read attachment ↗agio-011226xprxex991.htm · 8-K · 2026-01-12
EX-99.1 2 agio-011226xprxex991.htm EX-99.1 Document Exhibit 99.1 Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth • AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval • Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S. regulatory submission to follow • Company progressing early- and mid-stage pipeline in multipl…
Read attachment ↗